
AstraZeneca invests £75m to future-proof production facilities
pharmafile | December 15, 2015 | News story | Manufacturing and Production | AstraZeneca, manufacturing, production
AstraZeneca says it will invest £75m to future-proof a key production facility in Macclesfield, Cheshire.
The upgrade to the 48-year-old site will add a state of the art packing and warehouse facility to the North-West England location, which currently employs some 3,500 people. Although no new employment opportunities are expected to be created, the investment is expected to secure the existing jobs at the plant.
The new buildings at AZ’s second largest facility will replace an existing warehouse – which is currently being demolished – and will include packing lines for tablets and capsules, as well as an automated warehouse. Construction work is expected to begin early in the New Year, and follows the recent work on a new sterile production facility, also at the Macclesfield site.
AstraZeneca’s latest investment comes two years after the company axed 1,600 jobs at its Alderley Park complex, after moving its R&D operations to Cambridge.
The pharmaceutical giant was yesterday reported to be chasing a £3 billion-plus purchase of privately-held cancer drug developer Acerta Pharma, as the Anglo-Swedish company seeks to add new cancer drugs to its portfolio, including Acerta’s lead candidate acalabrutinib.
Joel Levy
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Brenntag and dsm-firmenich expand biopharma vitamin partnership
Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for …

BioDuro establishes joint manufacturing venture with Cenra
BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …





